The global cancer biomarkers market accounted for USD 15.09 billion in 2023 and is expected to reach at USD 62.14 billion by 2034 with a CAGR of 13.73% during the forecast period 2024-2034. The factors driving the growth of this market are the increasing global incidence of cancer, the aging population, the shift in focus towards early detection, technological advancements, the growing use of these tools in drug discovery and development, rising awareness, and government initiatives.
The diagnosis of diseases is giving way to a preventive and early detection approach in the healthcare industry. Cancer biomarkers have a critical role in the early and precise identification of cancer, facilitating prompt intervention and enhancing patient outcomes. The market for cancer biomarkers is expanding as a result of this change in emphasis. For instance, Servier and QIAGEN announced a collaboration in March 2023 to create a novel mIDH1 companion diagnostic test to support Servier's Hemato-Oncology Portfolio. It is a step toward the creation of a fresh diagnostic test to help detect acute myeloid leukemia (AML) in patients.
By type, the breast cancer segment accounted for the highest revenue-grossing segment in the global cancer biomarkers market in 2023 owing to the increased prevalence of breast cancer worldwide and the growing demand for early detection and personalized treatment options. For instance, in January 2022, Illumina formed a co-development relationship with SomaLogic to enhance the two leading firms in biomarker research. Illumina, the leader in next-generation sequencing (NGS), and SomaLogic, the leader in protein biomarker discovery, will collaborate to expedite clinical potential. Additionally, the lung cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the rapid advancements in lung cancer biomarker research, increasing awareness, and the development of targeted therapies for specific lung cancer subtypes.
By biomolecule, the genetic biomarkers segment accounted for the highest revenue-grossing segment in the global cancer biomarkers market in 2023 owing to the growing understanding of the role of genetic mutations in cancer development, which has led to increased adoption of genetic biomarker tests for diagnosis, prognosis, and treatment selection. For instance, in March 2024, Roche Diagnostics received FDA approval for their new Elecsys BRAF V600E mutation test, a blood test designed to detect a particular genetic mutation in individuals with melanoma. Additionally, the epigenetic biomarkers segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of the importance of epigenetic modifications in cancer progression and the development of innovative technologies enabling the detection and analysis of epigenetic biomarkers.
By application, the diagnostics segment accounted for the highest revenue-grossing segment in the global cancer biomarkers market in 2023 owing to the increasing demand for early cancer detection, screening, and monitoring, driving the adoption of biomarker-based diagnostic tests. For instance, in April 2024, Abbott Laboratories announced a partnership with PaigeAI to apply AI to digital pathology image processing for cancer diagnostics, potentially resulting in more effective and precise cancer detection. Additionally, the personalized medicine segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing emphasis on tailoring cancer treatments to individual patients based on their unique biomarker profiles, resulting in increased demand for personalized medicine approaches.
By end-user, the hospital segment accounted for the highest revenue-grossing segment in the global cancer biomarkers market in 2023 owing to the increased patient footfall in hospitals for cancer diagnosis, treatment, and follow-up care, driving demand for biomarker testing services within hospital settings. For instance, in May 2024, Thermo Fisher Scientific introduced the Ion Torrent G5 System, a next-generation sequencing platform intended for a thorough examination of genetic abnormalities in cancer patients. Additionally, the diagnostic laboratory segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for specialized biomarker testing services, increased outsourcing of diagnostic procedures, and technological advancements enhancing the efficiency and accuracy of diagnostic laboratory testing.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of cancer, advanced healthcare infrastructure, substantial investment in research and development, and supportive regulatory environment fostering biomarker innovation in North America. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing cancer incidence, improving healthcare infrastructure, rising disposable income, and growing awareness about the importance of early cancer detection and personalized treatment options in the Asia Pacific region. For instance, Qiagen (February 2024) collaborated with a biopharmaceutical business to create a supplemental diagnostic test for a targeted cancer treatment.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The diagnosis of diseases is giving way to a preventive and early detection approach in the healthcare industry. Cancer biomarkers have a critical role in the early and precise identification of cancer, facilitating prompt intervention and enhancing patient outcomes. The market for cancer biomarkers is expanding as a result of this change in emphasis. For instance, Servier and QIAGEN announced a collaboration in March 2023 to create a novel mIDH1 companion diagnostic test to support Servier's Hemato-Oncology Portfolio. It is a step toward the creation of a fresh diagnostic test to help detect acute myeloid leukemia (AML) in patients.
By type, the breast cancer segment accounted for the highest revenue-grossing segment in the global cancer biomarkers market in 2023 owing to the increased prevalence of breast cancer worldwide and the growing demand for early detection and personalized treatment options. For instance, in January 2022, Illumina formed a co-development relationship with SomaLogic to enhance the two leading firms in biomarker research. Illumina, the leader in next-generation sequencing (NGS), and SomaLogic, the leader in protein biomarker discovery, will collaborate to expedite clinical potential. Additionally, the lung cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the rapid advancements in lung cancer biomarker research, increasing awareness, and the development of targeted therapies for specific lung cancer subtypes.
By biomolecule, the genetic biomarkers segment accounted for the highest revenue-grossing segment in the global cancer biomarkers market in 2023 owing to the growing understanding of the role of genetic mutations in cancer development, which has led to increased adoption of genetic biomarker tests for diagnosis, prognosis, and treatment selection. For instance, in March 2024, Roche Diagnostics received FDA approval for their new Elecsys BRAF V600E mutation test, a blood test designed to detect a particular genetic mutation in individuals with melanoma. Additionally, the epigenetic biomarkers segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of the importance of epigenetic modifications in cancer progression and the development of innovative technologies enabling the detection and analysis of epigenetic biomarkers.
By application, the diagnostics segment accounted for the highest revenue-grossing segment in the global cancer biomarkers market in 2023 owing to the increasing demand for early cancer detection, screening, and monitoring, driving the adoption of biomarker-based diagnostic tests. For instance, in April 2024, Abbott Laboratories announced a partnership with PaigeAI to apply AI to digital pathology image processing for cancer diagnostics, potentially resulting in more effective and precise cancer detection. Additionally, the personalized medicine segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing emphasis on tailoring cancer treatments to individual patients based on their unique biomarker profiles, resulting in increased demand for personalized medicine approaches.
By end-user, the hospital segment accounted for the highest revenue-grossing segment in the global cancer biomarkers market in 2023 owing to the increased patient footfall in hospitals for cancer diagnosis, treatment, and follow-up care, driving demand for biomarker testing services within hospital settings. For instance, in May 2024, Thermo Fisher Scientific introduced the Ion Torrent G5 System, a next-generation sequencing platform intended for a thorough examination of genetic abnormalities in cancer patients. Additionally, the diagnostic laboratory segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for specialized biomarker testing services, increased outsourcing of diagnostic procedures, and technological advancements enhancing the efficiency and accuracy of diagnostic laboratory testing.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of cancer, advanced healthcare infrastructure, substantial investment in research and development, and supportive regulatory environment fostering biomarker innovation in North America. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing cancer incidence, improving healthcare infrastructure, rising disposable income, and growing awareness about the importance of early cancer detection and personalized treatment options in the Asia Pacific region. For instance, Qiagen (February 2024) collaborated with a biopharmaceutical business to create a supplemental diagnostic test for a targeted cancer treatment.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Biomolecule, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Cancer Biomarkers Market Report 2023 - 2034
Cancer Biomarkers Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Breast cancer
- Prostate cancer
- Colorectal cancer
- Cervical cancer
- Liver cancer
- Lung cancer
- Others
Cancer Biomarkers Market Analysis & Forecast by Biomolecule 2023 - 2034 (Revenue USD Bn)
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
- Others
Cancer Biomarkers Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Drug discovery and Development
- Diagnostics
- Personalized medicine
- Others
Cancer Biomarkers Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospital
- Specialty Clinics
- Diagnostic Laboratory
- Academic and research institute
- Others
Cancer Biomarkers Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cancer Biomarkers Market: Type Estimates & Trend Analysis
8. Cancer Biomarkers Market: Biomolecule Estimates & Trend Analysis
9. Cancer Biomarkers Market: Application Estimates & Trend Analysis
10. Cancer Biomarkers Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Cancer Biomarkers Market
13. Europe Global Cancer Biomarkers Market
14. Asia Pacific Global Cancer Biomarkers Market
15. Latin America Global Cancer Biomarkers Market
16. MEA Global Cancer Biomarkers Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Roche Diagnostics
- Abbott Laboratories
- Thermo Fisher Scientific
- Illumina Inc.
- Qiagen N.V.
- Bio-Rad Laboratories
- Agilent Technologies
- Siemens Healthineers
- Merck KGaA
- Bristol Myers Squibb
- Novartis AG
- BioMérieux SA
- Guardant Health
- Exact Sciences Corporation
- Myriad Genetics.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 15.09 Billion |
| Forecasted Market Value ( USD | $ 62.14 Billion |
| Compound Annual Growth Rate | 13.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
